Presentation is loading. Please wait.

Presentation is loading. Please wait.

Supplementary S1 HSC3 HSC3M3 HN5 HN30 H357 UMSCC74A UMSCC74B UMSCC11B

Published byDamian Goodwin Modified over 6 years ago

Similar presentations

Presentation on theme: "Supplementary S1 HSC3 HSC3M3 HN5 HN30 H357 UMSCC74A UMSCC74B UMSCC11B"— Presentation transcript:

1 Supplementary S1 HSC3 HSC3M3 HN5 HN30 H357 UMSCC74A UMSCC74B UMSCC11B
Age 63 73 unknown 74 N/A 65 59 Sex M F Origin cervical lymph node/tongue carcinoma metastatic from HSC3 in mice tongue pharynx base of tongue hypopharynx lymph node metastasis/ Tumour differentiation poorly diff. mod. diff. well diff. TNM T2N0M0 T1N0M0 T2N2aM0 T2N1M0 Stage II I V III Prior treatment CT/RT none CT p53 status mutant wild type Ras status HPV status negative

2 Supplementary S2 SM TRAIL HSC3 0.03 nM - HSC3M3 0.47 nM HN5 0.25 nM
6.7 ng/ml UMSCC74A 2.8 ng/ml UMSCC74B 28.3 ng/ml H357 82.1 ng/ml UMSCC11B 0.77 ng/ml UMSCC22B 110.3 ng/ml

3 Supplementary S3 SM sensitive TRAIL sensitive HSC3M3 HSC3 HN5 HN30
UMSCC11B UMSCC74A Isotype, TRAIL-R1, TRAIL-R2

4 Supplemental S4 A B Ctrl scr sh-C8 SM 2h 4h 6h 47 29 59 kDa 42 Casp-10
Casp-10 (cleaved) Actin B Ctrl HSC3 H357 2h 4h 6h TRAIL Casp-10 Casp-10 (cleaved) Actin 59 kDa 47 29 42

5 SUPPLEMENTAL S5 A C B Ctrl 2h 4h 6h HSC3 H357 SM HSC3 H357 HSC3 H357
89 kDa 34 22 42 19 17 PARP (cleaved) Casp-3 Casp-3 (cleaved) Bid Actin B Cyt c Tubulin scr sh-Bid Ctrl 3h SM 12 kDa 55

Download ppt "Supplementary S1 HSC3 HSC3M3 HN5 HN30 H357 UMSCC74A UMSCC74B UMSCC11B"

Similar presentations

Module 6: Clinical Stage and Grade. Introduction Stage and grade determine prognosis Staging reflects the clinical extent of the tumor Grading a tumor.

Module 6: Clinical Stage and Grade. Introduction Stage and grade determine prognosis Staging reflects the clinical extent of the tumor Grading a tumor.
00.111000.1110 A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S1 0.004.01.040.01.030.10.313100.01.11.

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S
Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.

Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.
H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.

H. AlHussain, I. Busca, L. Eapen,, S. El-Sayed The Ottawa Hospital Cancer Center, University of Ottawa Department of Radiation Oncology.
Renal Tumours n Mr C Dawson MS FRCS n Consultant Urologist n Fitzwilliam Hospital n Peterborough.

Renal Tumours n Mr C Dawson MS FRCS n Consultant Urologist n Fitzwilliam Hospital n Peterborough.
What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.

What is TNM? TNM is a system for classifying malignant tumours ! It is a cancer staging system, which describes the extent of a person's cancer ! Most.
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=
Analysis of tumour stage and treatment 26 REGISTRIES IN TOTAL –2: BREAST ONLY –2: CHILDREN ONLY DATE OF INCIDENCE RANGE: 1978-2003 YEARS OF DATA RANGE:

Analysis of tumour stage and treatment 26 REGISTRIES IN TOTAL –2: BREAST ONLY –2: CHILDREN ONLY DATE OF INCIDENCE RANGE: YEARS OF DATA RANGE:
DAHANCA 16 Planned post-radiation neck dissection vs salvage neck dissection in patients with N2-3 SCC of the head and neck treated with primary radiotherapy.

DAHANCA 16 Planned post-radiation neck dissection vs salvage neck dissection in patients with N2-3 SCC of the head and neck treated with primary radiotherapy.
Cancer Staging.

Cancer Staging.
Principles of Surgical Oncology Salah R. Elfaqih.

Principles of Surgical Oncology Salah R. Elfaqih.
AJCC Staging Moments AJCC TNM Staging 7th Edition Supraglottic Larynx Case #2 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New.

AJCC Staging Moments AJCC TNM Staging 7th Edition Supraglottic Larynx Case #2 Contributors: Jatin P. Shah, MD Memorial Sloan-Kettering Cancer Center, New.
Hairy leukoplakia Distinctive oral lesion Seen in immunocompromised patients 80% of patients with hairy leukoplakia have HIV infection.

Hairy leukoplakia Distinctive oral lesion Seen in immunocompromised patients 80% of patients with hairy leukoplakia have HIV infection.
Pharynx Sagittal view of the face and neck depicting the subdivisions of the pharynx as described in the text. Compton, C.C., Byrd, D.R., et al., Editors.

Pharynx Sagittal view of the face and neck depicting the subdivisions of the pharynx as described in the text. Compton, C.C., Byrd, D.R., et al., Editors.
© Cancer Research UK 2005 Registered charity number 1089464 Oral Cancer The statistics in this presentation are based on the Oral CancerStats report published.

© Cancer Research UK 2005 Registered charity number Oral Cancer The statistics in this presentation are based on the Oral CancerStats report published.
Carcinoma of the larynx

Carcinoma of the larynx
Principles of Surgical Oncology

Principles of Surgical Oncology
HEAD/NECK CARCINOMA 2002-2006 Johns Hopkins Hospital.

HEAD/NECK CARCINOMA Johns Hopkins Hospital.
Cancer of the Head and Neck and HPV Infection Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic.

Cancer of the Head and Neck and HPV Infection Andrew Urquhart MD, FACS Dept. Otolaryngology/Head and Neck Surgery Marshfield Clinic.

Similar presentations

Ads by Google